Standout Papers

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors 2021 2026 2022 2024299
  1. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors (2021)
    Leigh Marcus, Lola A. Fashoyin‐Aje et al. Clinical Cancer Research

Citation Impact

1 by Nobel laureates 8 from Science/Nature 55 standout
Sub-graph 1 of 24

Citing Papers

Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
2024 Standout
Targeting KRAS in cancer
2024 Standout
1 intermediate paper

Works of Reena Philip being referenced

Regulatory implications of ctDNA in immuno-oncology for solid tumors
2023
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer
2020

Author Peers

Author Oncology Cancer Research PRM Molecular Biology Last Decade Papers Cites
Reena Philip 552 273 278 386 23 1.0k
Kendall R. Walker 14 15 17 383 14 765
Maurício Cetra 1 18 43 684
Naveen B. Krishna 206 29 108 38 18 281
Katariina Castrén 205 135 91 238 10 453
Honglei Cai 13 414

All Works

Loading papers...

Rankless by CCL
2026